ANDA 74319, held by Purepac Pharm. Naproxen Sodium.
As of Nov 15, 2026, ANDA 74319 (Naproxen Sodium), held by Purepac Pharm, was not approved, with 0 approved supplements and 0 published complete response letters.
| Naproxen SodiumEQ 250MG BASE · tablet;oral | Naproxen Sodium | Discontinued |
| Naproxen SodiumEQ 500MG BASE · tablet;oral | Naproxen Sodium | Discontinued |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
